Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Zander

Showing results (441-450 of 456) with videos related to

Pageof 46
Sort By:
Psycho-Oncology|September 5, 2012
Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter studyAngela Scherwath, Lena Schirmer, Margitta Kruse, et al.
Bone Marrow Transplantation|December 14, 2011
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioningJ Casper, J Holowiecki, R Trenschel, et al.
Bone Marrow Transplantation|September 4, 2003
A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myelomaH Einsele, M Bamberg, W Budach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United StatesK Scott Baker, Fausto R Loberiza, Hongmei Yu, et al.
Haematologica|June 11, 2011
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trialTapani Ruutu, Liisa Volin, Dietrich W Beelen, et al.
Journal of Hematology & Oncology|June 26, 2017
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMTEolia Brissot, Myriam Labopin, Matthias Stelljes, et al.
Blood|April 7, 2011
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-FreseniusGérard Socié, Claudia Schmoor, Wolfgang A Bethge, et al.
The Lancet. Oncology|August 22, 2009
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trialJürgen Finke, Wolfgang A Bethge, Claudia Schmoor, et al.
Blood|October 9, 2009
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationNicolaus Kröger, Ernst Holler, Guido Kobbe, et al.
Blood|December 8, 2009
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IVSusanne Saussele, Michael Lauseker, Alois Gratwohl, et al.
Pageof 46

Showing results (441-450 of 456) with videos related to

Sort By:
Pageof 46
Psycho-Oncology|September 5, 2012
Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter studyAngela Scherwath, Lena Schirmer, Margitta Kruse, et al.
Bone Marrow Transplantation|December 14, 2011
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioningJ Casper, J Holowiecki, R Trenschel, et al.
Bone Marrow Transplantation|September 4, 2003
A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myelomaH Einsele, M Bamberg, W Budach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United StatesK Scott Baker, Fausto R Loberiza, Hongmei Yu, et al.
Haematologica|June 11, 2011
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trialTapani Ruutu, Liisa Volin, Dietrich W Beelen, et al.
Journal of Hematology & Oncology|June 26, 2017
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMTEolia Brissot, Myriam Labopin, Matthias Stelljes, et al.
Blood|April 7, 2011
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-FreseniusGérard Socié, Claudia Schmoor, Wolfgang A Bethge, et al.
The Lancet. Oncology|August 22, 2009
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trialJürgen Finke, Wolfgang A Bethge, Claudia Schmoor, et al.
Blood|October 9, 2009
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationNicolaus Kröger, Ernst Holler, Guido Kobbe, et al.
Blood|December 8, 2009
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IVSusanne Saussele, Michael Lauseker, Alois Gratwohl, et al.
Pageof 46